Legend Biotech Reports Strong Q4 & FY25 Results, CARVYKTI Sales Surge, Achieves Franchise Profitability

summarizeSummary

Legend Biotech announced strong Q4 and full year 2025 results, with CARVYKTI sales reaching $1.9 billion for the year and the franchise achieving profitability, alongside significant improvements in operating performance and a healthy cash position.

check_boxKey Events

• CARVYKTI Sales and Profitability

  CARVYKTI net trade sales reached approximately $555 million in Q4 2025 and $1.9 billion for the full year 2025. The CARVYKTI franchise achieved profitability for the full year 2025, and over 10,000 patients have been treated with the therapy.

• Significant Revenue Growth

  Total revenue for Q4 2025 increased to $306.3 million from $186.5 million in Q4 2024. Full year 2025 total revenue grew to $1,028.9 million from $627.3 million in 2024, primarily driven by CARVYKTI sales.

• Improved Financial Performance

  Operating loss significantly improved to $19.7 million in Q4 2025 from $79.3 million in Q4 2024. Adjusted net income for Q4 2025 was $2.5 million, a substantial improvement from an adjusted net loss of $59.0 million in Q4 2024.

• Robust Cash Position and Pipeline Progress

  The company maintained a strong balance sheet with approximately $949 million in cash and cash equivalents as of December 31, 2025, supporting a financial runway beyond 2026. Legend Biotech also advanced its early-stage cell therapy portfolio, including first-patient dosing of in vivo candidates.

auto_awesomeAnalysis

Legend Biotech reported robust financial results for Q4 and full year 2025, driven by exceptional performance of its lead product, CARVYKTI. The company achieved CARVYKTI franchise profitability for the full year and surpassed 10,000 patients treated, signaling strong commercial execution and market penetration. Significant improvements in operating loss and adjusted net income, with Q4 adjusted net income turning positive, demonstrate a positive trajectory towards overall company profitability. The substantial cash reserves provide a solid financial runway, supporting ongoing pipeline development and manufacturing expansion.